Ashley Chan

New trial data shows ivonescimab combined with chemotherapy significantly improves progression-free survival in EGFR-mutated non-small cell lung cancer patients.

Roy S. Herbst discusses advancements in EGFR-targeted therapies for early-stage NSCLC, highlighting improved survival rates and the role of molecular residual disease.

Researchers explore the impact of CD163-positive tumor-associated macrophages on the effectiveness of nivolumab in treating metastatic clear cell renal cell carcinoma.

Zanubrutinib shows superior progression-free survival in chronic lymphocytic leukemia compared with acalabrutinib plus venetoclax, according to recent analysis.

New data reveals bexobrutideg shows promising efficacy and safety in treating relapsed/refractory chronic lymphocytic leukemia, offering hope for patients.

New findings reveal RP1 combined with nivolumab enhances response rates in advanced melanoma, especially with deep tumor injections, showing promising safety and efficacy.

LB2102 showed early antitumor activity and no DLTs in small cell lung cancer and large cell neuroendocrine carcinoma.

Encorafenib and binimetinib show promise in reducing recurrence risk for high-risk BRAF V600-mutant melanoma, demonstrating a manageable safety profile.

Undetectable ctDNA at cycle 6 strongly predicts reduced progression/death risk in locally advanced cervical cancer patients treated with durvalumab/CRT or CRT alone.

Lifileucel therapy shows promising long-term survival and response rates in advanced melanoma patients, offering hope for those with limited treatment options.

Zanubrutinib shows durable efficacy in CLL/SLL with 17p deletions, according to 5-year SEQUOIA trial data.

Pembrolizumab combo before/after surgery and radiation significantly improved event-free survival in resectable advanced head and neck cancer per KEYNOTE-689, introducing a potential new standard of care.

Cretostimogene showed high and durable responses in heavily pretreated BCG-unresponsive NMIBC with CIS in a phase 3 trial. Well-tolerated with minimal high-grade TRAEs.

Tivozanib plus nivolumab had similar patient-reported outcomes to tivozanib alone in advanced kidney cancer after prior treatment, according to the TiNivo-2 study.

Obecabtagene autoleucel improved survival and response durability in B-cell acute lymphoblastic leukemia patients with minimal residual disease–negative remission.

Olaparib plus abiraterone improved survival vs placebo in BRCA-mutated metastatic castration-resistant prostate cancer.

Adagrasib plus cetuximab sustained clinical efficacy in KRAS G12C–mutant unresectable or metastatic colorectal cancer with longer follow-up, according to the KRYSTAL-1 trial.

A phase 2 trial showed ctDNA detection in HR-positive early breast cancer was linked to larger tumors, higher residual cancer burden, and increased recurrence after neoadjuvant endocrine therapy.

In a meta-analysis, second-generation BTK inhibitors were linked to a significantly low incidence of atrial fibrillation, overall cardiac adverse events, and heart failure in patients with B-cell hematologic malignancies.

Iopofosine I-131 delivered lasting efficacy and was well-tolerated in heavily pretreated patients with relapsed/refractory Waldenström macroglobulinemia.

Patients with platinum-sensitive relapsed ovarian cancer given maintenance olaparib/cediranib had similar progression-free and overall survival rates vs those given olaparib alone.

A combination of lenvatinib, pembrolizumab, and TACE significantly improved progression-free survival in patients with intermediate-stage hepatocellular carcinoma compared to dual placebo and TACE.

Encorafenib plus binimetinib demonstrated antitumor activity in patients with treatment-naive BRAF V600E-mutant advanced non–small cell lung cancer.

Results from the ASTREON trial showed a similar safety profile of oral azacitidine at a dose of 200-mg and 300-mg in patients with lower- to intermediate-risk MDS.

Oncological outcomes improved with the addition of abiraterone acetate (Zytiga) plus prednisone (AAP) and apalutamide (Erleada) after radical prostatectomy and did not significantly affect health-related quality of life.

The updated data of larotrectinib as a treatment in TRK fusion GI cancers continued to demonstrate optimal responses, survival, and safety.

A comparison of asciminib and bosutinib demonstrated greater efficacy and safety/tolerability with asciminib for patients with chronic phase chronic myeloid leukemia.